Document:

BCANDID CORPORATION

BCANDID CORPORATION

1999 EQUITY INCENTIVE PLAN

Adopted January 8, 1999

Approved By Stockholders January 8, 1999

Termination Date:  January 7, 2009

1.     PURPOSES.

          (a)     Eligible Stock Award Recipients.  The persons eligible to receive Stock Awards are the Employees, Directors and Consultants of the Company and
its Affiliates.

          (b)     Available Stock Awards.  The purpose of the Plan is to provide a means by which eligible recipients of Stock Awards may be given an opportunity
to benefit from increases in value of the Common Stock through the granting of the following Stock Awards:  (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) stock appreciation rights, (iv) stock bonuses and (v) rights to acquire
restricted stock.

          (c)     General Purpose.  The Company, by means of the Plan, seeks to retain the services of the group of persons eligible to receive Stock Awards, to
secure and retain the services of new members of this group and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Affiliates.

2.     DEFINITIONS.

          (a)     "Affiliate" means any parent corporation or subsidiary corporation of the Company, whether now or hereafter existing, as those terms are
defined in Sections 424(e) and (f), respectively, of the Code.

          (b)     "Board" means the Board of Directors of the Company.

          (c)     "Code" means the Internal Revenue Code of 1986, as amended.

          (d)     "Committee" means a Committee appointed by the Board in accordance with subsection 3(c).

          (e)     "Common Stock" means the common stock of the Company.

          (f)     "Company" means bCandid Corporation, a Delaware corporation.

          (g)     "Consultant" means any person, including an advisor, (i) engaged by the Company or an Affiliate to render consulting or advisory services and
who is compensated for such services or (ii) who is a member of the Board of Directors of an Affiliate.  However, the term "Consultant" shall not include either Directors of the Company who are not compensated by the Company for their services as
Directors or Directors of the Company who are merely paid a director's fee by the Company for their services as Directors.

          (h)     "Continuous Service" means that the Participant's service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is
not interrupted or terminated.  The Participant's Continuous Service shall not be deemed to have terminated merely because of a change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or
Director or a change in the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant's Continuous Service.  For example, a change in status from an Employee of the Company to a
Consultant of an Affiliate or a Director of the Company will not constitute an interruption of Continuous Service.  The Board or the chief executive officer of the Company, in that party's sole discretion, may determine whether Continuous Service shall be
considered interrupted in the case of any leave of absence approved by that party, including sick leave, military leave or any other personal leave.

          (i)     "Covered Employee" means the chief executive officer and the four (4) other highest compensated officers of the Company for whom total
compensation is required to be reported to stockholders under the Exchange Act, as determined for purposes of Section 162(m) of the Code.

          (j)     "Director" means a member of the Board of Directors of the Company.

          (k)     "Disability" means the permanent and total disability of a person within the meaning of Section 22(e)(3) of the Code.

          (l)     "Employee" means any person employed by the Company or an Affiliate.  Mere service as a Director or payment of a director's fee by the Company
or an Affiliate shall not be sufficient to constitute "employment" by the Company or an Affiliate.

          (m)     "Exchange Act" means the Securities Exchange Act of 1934, as amended.

          (n)     "Fair Market Value" means, as of any date, the value of the Common Stock determined as follows:

                    (i)     If the Common Stock is listed on any established stock exchange or traded on the
Nasdaq National Market or the Nasdaq SmallCap Market, the Fair Market Value of a share of Common Stock shall be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange or market (or the exchange or
market with the greatest volume of trading in the Common Stock) on the last market trading day prior to the day of determination, as reported in The Wall Street Journal or such other source as the Board deems reliable.

                    (ii)     In the absence of such markets for the Common Stock, the Fair Market Value shall
be determined in good faith by the Board.

          (o)     "Incentive Stock Option" means an Option intended to qualify as an incentive stock option within the meaning of Section 422 of the Code and the
regulations promulgated thereunder.

          (p)     "Listing Date" means the first date upon which any security of the Company is listed (or approved for listing) upon notice of issuance on any
securities exchange or designated (or approved for designation) upon notice of issuance as a national market security on an interdealer quotation system.

          (q)     "Non-Employee Director" means a Director of the Company who either (i) is not a current Employee or Officer of the Company or its parent or a
subsidiary, does not receive compensation (directly or indirectly) from the Company or its parent or a subsidiary for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be
required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act ("Regulation S-K")), does not possess an interest in any other transaction as to which disclosure would be required under Item 404(a) of Regulation S-K and is not
engaged in a business relationship as to which disclosure would be required under Item 404(b) of Regulation S-K; or (ii) is otherwise considered a "non-employee director" for purposes of Rule 16b-3.

          (r)     "Nonstatutory Stock Option" means an Option not intended to qualify as an Incentive Stock Option.

          (s)     "Officer" means (i) before the Listing Date, any person designated by the Company as an officer and (ii) on and after the Listing Date, a
person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules and regulations promulgated thereunder.

          (t)     "Option" means an Incentive Stock Option or a Nonstatutory Stock Option granted pursuant to the Plan.

          (u)     "Option Agreement" means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an individual
Option grant.  Each Option Agreement shall be subject to the terms and conditions of the Plan.

          (v)     "Optionholder" means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding
Option.

          (w)     "Outside Director" means a Director of the Company who either (i) is not a current employee of the Company or an "affiliated corporation"
(within the meaning of Treasury Regulations promulgated under Section 162(m) of the Code), is not a former employee of the Company or an "affiliated corporation" receiving compensation for prior services (other than benefits under a tax qualified pension
plan), was not an officer of the Company or an "affiliated corporation" at any time and is not currently receiving direct or indirect remuneration from the Company or an "affiliated corporation" for services in any capacity other than as a Director or
(ii) is otherwise considered an "outside director" for purposes of Section 162(m) of the Code.

          (x)     "Participant" means a person to whom a Stock Award is granted pursuant to the Plan or, if applicable, such other person who holds an
outstanding Stock Award.

          (y)     "Plan" means this bCandid Corporation 1999 Equity Incentive Plan.

          (z)     "Rule 16b-3" means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.

          (aa)     "Securities Act" means the Securities Act of 1933, as amended.

          (bb)     "Stock Award" means any right granted under the Plan, including an Option, a stock appreciation right, a stock bonus and a right to acquire
restricted stock.

          (cc)     "Stock Award Agreement" means a written agreement between the Company and a holder of a Stock Award evidencing the terms and conditions of an
individual Stock Award grant.  Each Stock Award Agreement shall be subject to the terms and conditions of the Plan.

          (dd)     "Ten Percent Stockholder" means a person who owns (or is deemed to own pursuant to Section 424(d) of the Code) stock possessing more than ten
percent (10%) of the total combined voting power of all classes of stock of the Company or of any of its Affiliates.

3.     ADMINISTRATION.

          (a)     Administration by Board.  The Board shall administer the Plan unless and until the Board delegates administration to a Committee, as provided
in subsection 3(c).

          (b)     Powers of Board.  The Board shall have the power, subject to, and within the limitations of, the express provisions of the Plan:

                    (i)     To determine from time to time which of the persons eligible under the Plan shall
be granted Stock Awards; when and how each Stock Award shall be granted; what type or combination of types of Stock Award shall be granted; the provisions of each Stock Award granted (which need not be identical), including the time or times when a person
shall be permitted to receive stock pursuant to a Stock Award; and the number of shares with respect to which a Stock Award shall be granted to each such person.

                    (ii)     To construe and interpret the Plan and Stock Awards granted under it, and to
establish, amend and revoke rules and regulations for its administration.  The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner and to the extent it shall deem
necessary or expedient to make the Plan fully effective.

                    (iii)     To amend the Plan or a Stock Award as provided in Section 12.

                    (iv)     Generally, to exercise such powers and to perform such acts as the Board deems
necessary or expedient to promote the best interests of the Company which are not in conflict with the provisions of the Plan.

          (c)     Delegation to Committee.

                    (i)     General.  The Board may delegate administration of the Plan to a Committee or
Committees of one or more members of the Board, and the term "Committee" shall apply to any person or persons to whom such authority has been delegated.  If administration is delegated to a Committee, the Committee shall have, in connection with the
administration of the Plan, the powers theretofore possessed by the Board, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board shall
thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board.  The Board may abolish the Committee at any time and revest in the
Board the administration of the Plan.

                    (ii)     Committee Composition when Common Stock is Publicly Traded.  At such time as the
Common Stock is publicly traded, in the discretion of the Board, a Committee may consist solely of two or more Outside Directors, in accordance with Section 162(m) of the Code, and/or solely of two or more Non-Employee Directors, in accordance with Rule
16b-3.  Within the scope of such authority, the Board or the Committee may (1) delegate to a committee of one or more members of the Board who are not Outside Directors, the authority to grant Stock Awards to eligible persons who are either (a) not then
Covered Employees and are not expected to be Covered Employees at the time of recognition of income resulting from such Stock Award or (b) not persons with respect to whom the Company wishes to comply with Section 162(m) of the Code and/or (2) delegate to
a committee of one or more members of the Board who are not Non-Employee Directors the authority to grant Stock Awards to eligible persons who are not then subject to Section 16 of the Exchange Act.

4.     SHARES SUBJECT TO THE PLAN.

          (a)     Share Reserve.  Subject to the provisions of Section 11 relating to adjustments upon changes in stock, the stock that may be issued pursuant to
Stock Awards shall not exceed in the aggregate one million five hundred thousand (1,500,000) shares of Common Stock. 

          (b)     Reversion of Shares to the Share Reserve.  If any Option shall for any reason expire or otherwise terminate, in whole or in part, without
having been exercised in full, the stock not acquired under such Option shall revert to and again become available for issuance under the Plan.  Shares subject to stock appreciation rights exercised in accordance with the Plan shall not be available for
subsequent issuance under the Plan.

          (c)     Source of Shares.  The stock subject to the Plan may be unissued shares or reacquired shares, bought on the market or otherwise.

5.     ELIGIBILITY.

          (a)     Eligibility for Specific Stock Awards.  Incentive Stock Options may be granted only to Employees.  Stock Awards other than Incentive Stock
Options may be granted to Employees, Directors and Consultants.

          (b)     Ten Percent Stockholders.  No Ten Percent Stockholder shall be eligible for the grant of an Incentive Stock Option unless the exercise price of
such Option is at least one hundred ten percent (110%) of the Fair Market Value of the Common Stock at the date of grant and the Option is not exercisable after the expiration of five (5) years from the date of grant. 

          (c)     Section 162(m) Limitation.  Subject to the provisions of Section 11 relating to adjustments upon changes in stock, no employee shall be
eligible to be granted Stock Awards covering more than four hundred twenty-five thousand (425,000) shares of the Common Stock during any calendar year.  This subsection 5(c) shall not apply prior to the Listing Date and, following the Listing Date, this
subsection 5(c) shall not apply until (i) the earliest of:  (1) the first material modification of the Plan (including any increase in the number of shares reserved for issuance under the Plan in accordance with Section 4); (2) the issuance of all of the
shares of Common Stock reserved for issuance under the Plan; (3) the expiration of the Plan; or (4) the first meeting of stockholders at which Directors of the Company are to be elected that occurs after the close of the third calendar year following the
calendar year in which occurred the first registration of an equity security under Section 12 of the Exchange Act; or (ii) such other date required by Section 162(m) of the Code and the rules and regulations promulgated thereunder.

6.     OPTION PROVISIONS.

          Each Option shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate.  All Options shall be separately designated Incentive Stock
Options or Nonstatutory Stock Options at the time of grant, and a separate certificate or certificates will be issued for shares purchased on exercise of each type of Option.  The provisions of separate Options need not be identical, but each Option shall
include (through incorporation of provisions hereof by reference in the Option or otherwise) the substance of each of the following provisions:

          (a)     Term.  Subject to the provisions of subsection 5(b) regarding Ten Percent Stockholders, no Incentive Stock Option shall be exercisable after
the expiration of ten (10) years from the date it was granted.

          (b)     Exercise Price of an Incentive Stock Option.  Subject to the provisions of subsection 5(b) regarding Ten Percent Stockholders, the exercise
price of each Incentive Stock Option shall be not less than one hundred percent (100%) of the Fair Market Value of the stock subject to the Option on the date the Option is granted.  Notwithstanding the foregoing, an Incentive Stock Option may be granted
with an exercise price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section 424(a) of the Code.

          (c)     Exercise Price of a Nonstatutory Stock Option.  The exercise price of each Nonstatutory Stock Option shall be not less than eighty-five percent
(85%) of the Fair Market Value of the stock subject to the Option on the date the Option is granted.  Notwithstanding the foregoing, a Nonstatutory Stock Option may be granted with an exercise price lower than that set forth in the preceding sentence if
such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section 424(a) of the Code.

          (d)     Consideration.  The purchase price of stock acquired pursuant to an Option shall be paid, to the extent permitted by applicable statutes and
regulations, either (i) in cash at the time the Option is exercised or (ii) at the discretion of the Board at the time of the grant of the Option (or subsequently in the case of a Nonstatutory Stock Option) (1) by delivery to the Company of other Common
Stock, (2) according to a deferred payment or other arrangement (which may include, without limiting the generality of the foregoing, the use of other Common Stock) with the Participant or (3) in any other form of legal consideration that may be
acceptable to the Board; provided, however, that at any time that the Company is incorporated in Delaware, payment of the Common Stock's "par value," as defined in the Delaware General Corporation Law, shall not be made by deferred payment.

          In the case of any deferred payment arrangement, interest shall be compounded at least annually and shall be charged at the minimum rate of interest necessary to avoid the
treatment as interest, under any applicable provisions of the Code, of any amounts other than amounts stated to be interest under the deferred payment arrangement.  

          (e)     Transferability of an Incentive Stock Option.  An Incentive Stock Option shall not be transferable except by will or by the laws of descent and
distribution and shall be exercisable during the lifetime of the Optionholder only by the Optionholder.  Notwithstanding the foregoing, the Optionholder may, by delivering written notice to the Company, in a form satisfactory to the Company, designate a
third party who, in the event of the death of the Optionholder, shall thereafter be entitled to exercise the Option.

           (f)     Transferability of a Nonstatutory Stock Option.  A Nonstatutory Stock Option shall be transferable to the extent provided in the Option
Agreement.  If the Nonstatutory Stock Option does not provide for transferability, then the Nonstatutory Stock Option shall not be transferable except by will or by the laws of descent and distribution and shall be exercisable during the lifetime of the
Optionholder only by the Optionholder.  Notwithstanding the foregoing, the Optionholder may, by delivering written notice to the Company, in a form satisfactory to the Company, designate a third party who, in the event of the death of the Optionholder,
shall thereafter be entitled to exercise the Option.

          (g)     Vesting Generally.  The total number of shares of Common Stock subject to an Option may, but need not, vest and therefore become exercisable in
periodic installments which may, but need not, be equal.  The Option may be subject to such other terms and conditions on the time or times when it may be exercised (which may be based on performance or other criteria) as the Board may deem appropriate.
The vesting provisions of individual Options may vary.  The provisions of this subsection 6(g) are subject to any Option provisions governing the minimum number of shares as to which an Option may be exercised.

          (h)     Termination of Continuous Service.  In the event an Optionholder's Continuous Service terminates (other than upon the Optionholder's death or
Disability), the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise it as of the date of termination) but only within such period of time ending on the earlier of (i) the date three (3) months
following the termination of the Optionholder's Continuous Service (or such longer or shorter period specified in the Option Agreement), or (ii) the expiration of the term of the Option as set forth in the Option Agreement.  If, after termination, the
Optionholder does not exercise his or her Option within the time specified in the Option Agreement, the Option shall terminate.

          (i)     Extension of Termination Date.  An Optionholder's Option Agreement may also provide that if the exercise of the Option following the
termination of the Optionholder's Continuous Service (other than upon the Optionholder's death or Disability) would be prohibited at any time solely because the issuance of shares would violate the registration requirements under the Securities Act, then
the Option shall terminate on the earlier of (i) the expiration of the term of the Option set forth in subsection 6(a) or (ii) the expiration of a period of three (3) months after the termination of the Optionholder's Continuous Service during which the
exercise of the Option would not be in violation of such registration requirements.

          (j)     Disability of Optionholder.  In the event an Optionholder's Continuous Service terminates as a result of the Optionholder's Disability, the
Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise it as of the date of termination), but only within such period of time ending on the earlier of (i) the date twelve (12) months following such
termination (or such longer or shorter period specified in the Option Agreement) or (ii) the expiration of the term of the Option as set forth in the Option Agreement.  If, after termination, the Optionholder does not exercise his or her Option within the
time specified herein, the Option shall terminate.

          (k)     Death of Optionholder.  In the event (i) an Optionholder's Continuous Service terminates as a result of the Optionholder's death or (ii) the
Optionholder dies within the period (if any) specified in the Option Agreement after the termination of the Optionholder's Continuous Service for a reason other than death, then the Option may be exercised (to the extent the Optionholder was entitled to
exercise the Option as of the date of death) by the Optionholder's estate, by a person who acquired the right to exercise the Option by bequest or inheritance or by a person designated to exercise the option upon the Optionholder's death pursuant to
subsection 6(e) or 6(f), but only within the period ending on the earlier of (1) the date eighteen (18) months following the date of death (or such longer or shorter period specified in the Option Agreement) or (2) the expiration of the term of such
Option as set forth in the Option Agreement.  If, after death, the Option is not exercised within the time specified herein, the Option shall terminate.

          (l)     Early Exercise.  The Option may, but need not, include a provision whereby the Optionholder may elect at any time before the Optionholder's
Continuous Service terminates to exercise the Option as to any part or all of the shares subject to the Option prior to the full vesting of the Option.  Any unvested shares so purchased may be subject to an unvested share repurchase option in favor of the
Company or to any other restriction the Board determines to be appropriate.

          (m)     Right of First Refusal.  The Option may, but need not, include a provision whereby the Company may elect, prior to the Listing Date, to
exercise a right of first refusal following receipt of notice from the Optionholder of the intent to transfer all or any part of the shares received upon the exercise of the Option.  Except as expressly provided in this subsection 6(m), such right of
first refusal shall otherwise comply with any applicable provisions of the Bylaws of the Company.

          (n)     Re-Load Options.  Without in any way limiting the authority of the Board to make or not to make grants of Options hereunder, the Board shall
have the authority (but not an obligation) to include as part of any Option Agreement a provision entitling the Optionholder to a further Option (a "Re-Load Option") in the event the Optionholder exercises the Option evidenced by the Option Agreement, in
whole or in part, by surrendering other shares of Common Stock in accordance with this Plan and the terms and conditions of the Option Agreement.  Any such Re-Load Option shall (i) provide for a number of shares equal to the number of shares surrendered
as part or all of the exercise price of such Option; (ii) have an expiration date which is the same as the expiration date of the Option the exercise of which gave rise to such Re-Load Option; and (iii) have an exercise price which is equal to one hundred
percent (100%) of the Fair Market Value of the Common Stock subject to the Re-Load Option on the date of exercise of the original Option.  Notwithstanding the foregoing, a Re-Load Option shall be subject to the same exercise price and term provisions
heretofore described for Options under the Plan.

          Any such Re-Load Option may be an Incentive Stock Option or a Nonstatutory Stock Option, as the Board may designate at the time of the grant of the original Option; provided,
however, that the designation of any Re-Load Option as an Incentive Stock Option shall be subject to the one hundred thousand dollar ($100,000) annual limitation on the exercisability of Incentive Stock Options described in subsection 10(d) and in Section
422(d) of the Code.  There shall be no Re-Load Options on a Re-Load Option.  Any such Re-Load Option shall be subject to the availability of sufficient shares under subsection 4(a) and the "Section 162(m) Limitation" on the grants of Options under
subsection 5(c) and shall be subject to such other terms and conditions as the Board may determine which are not inconsistent with the express provisions of the Plan regarding the terms of Options.

7.     PROVISIONS OF STOCK AWARDS OTHER THAN OPTIONS.

          (a)     Stock Bonus Awards.  Each stock bonus agreement shall be in such form and shall contain such terms and conditions as the Board shall deem
appropriate.  The terms and conditions of stock bonus agreements may change from time to time, and the terms and conditions of separate stock bonus agreements need not be identical, but each stock bonus agreement shall include (through incorporation of
provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:  

                    (i)     Consideration.  A stock bonus shall be awarded in consideration for past services
actually rendered to the Company or an Affiliate for its benefit.

                    (ii)     Vesting.  Shares of Common Stock awarded under the stock bonus agreement may, but
need not, be subject to a share repurchase option in favor of the Company in accordance with a vesting schedule to be determined by the Board.

                    (iii)     Termination of Participant's Continuous Service.  In the event a Participant's
Continuous Service terminates, the Company may reacquire any or all of the shares of Common Stock held by the Participant which have not vested as of the date of termination under the terms of the stock bonus agreement.

                    (iv)     Transferability.  Rights to acquire shares under the stock bonus agreement shall
be transferable by the Participant only upon such terms and conditions as are set forth in the stock bonus agreement, as the Board shall determine in its discretion, so long as stock awarded under the stock bonus agreement remains subject to the terms of
the stock bonus agreement.

          (b)     Restricted Stock Awards.  Each restricted stock purchase agreement shall be in such form and shall contain such terms and conditions as the
Board shall deem appropriate.  The terms and conditions of the restricted stock purchase agreements may change from time to time, and the terms and conditions of separate restricted stock purchase agreements need not be identical, but each restricted
stock purchase agreement shall include (through incorporation of provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:

                    (i)     Purchase Price.  The purchase price under each restricted stock purchase agreement
shall be such amount as the Board shall determine and designate in such restricted stock purchase agreement.  The purchase price shall not be less than eighty-five percent (85%) of the stock's Fair Market Value on the date such award is made or at the
time the purchase is consummated.

                    (ii)     Consideration.  The purchase price of stock acquired pursuant to the restricted
stock purchase agreement shall be paid either:  (i) in cash at the time of purchase; (ii) at the discretion of the Board, according to a deferred payment or other arrangement with the Participant; or (iii) in any other form of legal consideration that may
be acceptable to the Board in its discretion; provided, however, that at any time that the Company is incorporated in Delaware, payment of the Common Stock's "par value," as defined in the Delaware General Corporation Law, shall not be made by deferred
payment.

                    (iii)     Vesting.  Shares of Common Stock acquired under the restricted stock purchase
agreement may, but need not, be subject to a share repurchase option in favor of the Company in accordance with a vesting schedule to be determined by the Board.

                    (iv)     Termination of Participant's Continuous Service.  In the event a Participant's
Continuous Service terminates, the Company may repurchase or otherwise reacquire any or all of the shares of Common Stock held by the Participant which have not vested as of the date of termination under the terms of the restricted stock purchase agreement.

                    (v)     Transferability.  Rights to acquire shares under the restricted stock purchase
agreement shall be transferable by the Participant only upon such terms and conditions as are set forth in the restricted stock purchase agreement, as the Board shall determine in its discretion, so long as stock awarded under the restricted stock
purchase agreement remains subject to the terms of the restricted stock purchase agreement.

          (c)     Stock Appreciation Rights.

                    (i)     Authorized Rights.  The following three types of stock appreciation rights shall be
authorized for issuance under the Plan:

                           (1)     Tandem Rights.  A "Tandem Right" means a
stock appreciation right granted appurtenant to an Option which is subject to the same terms and conditions applicable to the particular Option grant to which it pertains with the following exceptions:  The Tandem Right shall require the holder to elect
between the exercise of the underlying Option for shares of Common Stock and the surrender, in whole or in part, of such Option for an appreciation distribution.  The appreciation distribution payable on the exercised the Tandem Right shall be in cash
(or, if so provided, in an equivalent number of shares of Common Stock based on Fair Market Value on the date of the Option surrender) in an amount up to the excess of (A) the Fair Market Value (on the date of the Option surrender) of the number of shares
of Common Stock covered by that portion of the surrendered Option in which the Optionholder is vested over (B) the aggregate exercise price payable for such vested shares.

                           (2)     Concurrent Rights.  A "Concurrent Right"
means a stock appreciation right granted appurtenant to an Option which applies to all or a portion of the shares of Common Stock subject to the underlying Option and which is subject to the same terms and conditions applicable to the particular Option
grant to which it pertains with the following exceptions:  A Concurrent Right shall be exercised automatically at the same time the underlying Option is exercised with respect to the particular shares of Common Stock to which the Concurrent Right
pertains.  The appreciation distribution payable on an exercised Concurrent Right shall be in cash (or, if so provided, in an equivalent number of shares of Common Stock based on Fair Market Value on the date of the exercise of the Concurrent Right) in an
amount equal to such portion as determined by the Board at the time of the grant of the excess of (A) the aggregate Fair Market Value (on the date of the exercise of the Concurrent Right) of the vested shares of Common Stock purchased -under the
underlying Option which have Concurrent Rights appurtenant to them over (B) the aggregate exercise price paid for such shares.

                           (3)     Independent Rights.  An "Independent
Right" means a stock appreciation right granted independently of any Option but which is subject to the same terms and conditions applicable to a Nonstatutory Stock Option with the following exceptions:  An Independent Right shall be denominated in share
equivalents.  The appreciation distribution payable on the exercised Independent Right shall be not greater than an amount equal to the excess of (a) the aggregate Fair Market Value (on the date of the exercise of the Independent Right) of a number of
shares of Company stock equal to the number of share equivalents in which the holder is vested under such Independent Right, and with respect to which the holder is exercising the Independent Right on such date, over (b) the aggregate Fair Market Value
(on the date of the grant of the Independent Right) of such number of shares of Company stock.  The appreciation distribution payable on the exercised Independent Right shall be in cash or, if so provided, in an equivalent number of shares of Common Stock
based on Fair Market Value on the date of the exercise of the Independent Right.

                    (ii)     Relationship to Options.  Stock appreciation rights appurtenant to Incentive Stock
Options may be granted only to Employees.  The "Section 162(m) Limitation" provided in subsection 5(c) and any authority to reprice Options shall apply as well to the grant of stock appreciation rights.

                    (iii)     Exercise.  To exercise any outstanding stock appreciation right, the holder shall
provide written notice of exercise to the Company in compliance with the provisions of the Stock Award Agreement evidencing such right.   Except as provided in subsection 5(c) regarding the "Section 162(m) Limitation," no limitation shall exist on the
aggregate amount of cash payments that the Company may make under the Plan in connection with the exercise of a stock appreciation right.

8.     COVENANTS OF THE COMPANY.

          (a)     Availability of Shares.  During the terms of the Stock Awards, the Company shall keep available at all times the number of shares of Common
Stock required to satisfy such Stock Awards.

          (b)     Securities Law Compliance.  The Company shall seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such
authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; provided, however, that this undertaking shall not require the Company to register under the Securities Act the Plan, any
Stock Award or any stock issued or issuable pursuant to any such Stock Award.  If, after reasonable efforts, the Company is unable to obtain from any such regulatory commission or agency the authority which counsel for the Company deems necessary for the
lawful issuance and sale of stock under the Plan, the Company shall be relieved from any liability for failure to issue and sell stock upon exercise of such Stock Awards unless and until such authority is obtained.

9.     USE OF PROCEEDS FROM STOCK.

          Proceeds from the sale of stock pursuant to Stock Awards shall constitute general funds of the Company.

10.     MISCELLANEOUS.

          (a)     Acceleration of Exercisability and Vesting.  The Board shall have the power to accelerate the time at which a Stock Award may first be
exercised or the time during which a Stock Award or any part thereof will vest in accordance with the Plan, notwithstanding the provisions in the Stock Award stating the time at which it may first be exercised or the time during which it will vest.

          (b)     Stockholder Rights.  No Participant shall be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares
subject to such Stock Award unless and until such Participant has satisfied all requirements for exercise of the Stock Award pursuant to its terms.

          (c)     No Employment or other Service Rights.  Nothing in the Plan or any instrument executed or Stock Award granted pursuant thereto shall confer
upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or shall affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with
or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant's agreement with the Company or an Affiliate or (iii) the service of a Director pursuant to the Bylaws of the Company or an Affiliate,
and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.

          (d)     Incentive Stock Option $100,000 Limitation.  To the extent that the aggregate Fair Market Value (determined at the time of grant) of stock with
respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and its Affiliates) exceeds one hundred thousand dollars ($100,000), the Options or portions thereof
which exceed such limit (according to the order in which they were granted) shall be treated as Nonstatutory Stock Options.

          (e)     Investment Assurances.  The Company may require a Participant, as a condition of exercising or acquiring stock under any Stock Award, (i) to
give written assurances satisfactory to the Company as to the Participant's knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced
in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Stock Award; and (ii) to give written assurances satisfactory to the Company stating
that the Participant is acquiring the stock subject to the Stock Award for the Participant's own account and not with any present intention of selling or otherwise distributing the stock.  The foregoing requirements, and any assurances given pursuant to
such requirements, shall be inoperative if (iii) the issuance of the shares upon the exercise or acquisition of stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act or (iv) as to
any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws.  The Company may, upon advice of counsel to the Company, place legends on
stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the stock.

          (f)     Withholding Obligations.  To the extent provided by the terms of a Stock Award Agreement, the Participant may satisfy any federal, state or
local tax withholding obligation relating to the exercise or acquisition of stock under a Stock Award by any of the following means (in addition to the Company's right to withhold from any compensation paid to the Participant by the Company) or by a
combination of such means:  (i) tendering a cash payment; (ii) authorizing the Company to withhold shares from the shares of the Common Stock otherwise issuable to the participant as a result of the exercise or acquisition of stock under the Stock Award;
or (iii) delivering to the Company owned and unencumbered shares of the Common Stock.

11.     ADJUSTMENTS UPON CHANGES IN STOCK.

          (a)     Capitalization Adjustments.  If any change is made in the stock subject to the Plan, or subject to any Stock Award, without the receipt of
consideration by the Company (through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, exchange of shares, change in
corporate structure or other transaction not involving the receipt of consideration by the Company), the Plan will be appropriately adjusted in the class(es) and maximum number of securities subject to the Plan pursuant to subsection 4(a) and the maximum
number of securities subject to award to any person pursuant to subsection 5(c), and the outstanding Stock Awards will be appropriately adjusted in the class(es) and number of securities and price per share of stock subject to such outstanding Stock
Awards.  The Board shall make such adjustments in good faith, and its determination shall be final, binding and conclusive.  (The conversion of any convertible securities of the Company shall not be treated as a transaction "without receipt of
consideration" by the Company.)

          (b)     Change in Control--Dissolution or Liquidation.  In the event of a dissolution or liquidation of the Company, then all outstanding Stock Awards
shall terminate immediately prior to such event.

          (c)     Change in Control--Asset Sale, Merger, Consolidation or Reverse Merger.  In the event of (i) a sale, lease or other disposition of all or
substantially all of the assets of the Company, (ii) a consolidation or merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, in which the stockholders of the Company immediately prior
to such consolidation, merger or reorganization, own less than 50% of the outstanding voting power of the surviving entity (or its parent) following the consolidation, merger or reorganization or (iii) any transaction (or series of related transactions
involving a person or entity, or a group of affiliated persons or entities) in which in excess of fifty percent (50%) of the Company's outstanding voting power is transferred (any of the above, a "Change of Control"), then any surviving corporation or
acquiring corporation shall assume any Stock Awards outstanding under the Plan or shall substitute similar stock awards (including an award to acquire the same consideration paid to the stockholders in the transaction described in this subsection 11(c)
for those outstanding under the Plan.  In the event any surviving corporation or acquiring corporation refuses to assume such Stock Awards or to substitute similar stock awards for those outstanding under the Plan, then with respect to Stock Awards held
by Participants whose Continuous Service has not terminated, the vesting of such Stock Awards (and, if applicable, the time during which such Stock Awards may be exercised) shall be accelerated in full, and the Stock Awards shall terminate if not
exercised (if applicable) at or prior to such event.  With respect to any other Stock Awards outstanding under the Plan, such Stock Awards shall terminate if not exercised (if applicable) prior to such event.

          In the event of a Change in Control, the Company shall give each optionholder written notice of such Change in Control at least ten (10) days prior to the closing of such
transaction. 

12.     AMENDMENT OF THE PLAN AND STOCK AWARDS.

          (a)     Amendment of Plan.  The Board at any time, and from time to time, may amend the Plan.  However, except as provided in Section 11 relating to
adjustments upon changes in stock, no amendment shall be effective unless approved by the stockholders of the Company to the extent stockholder approval is necessary to satisfy the requirements of Section 422 of the Code, Rule 16b-3 or any Nasdaq or
securities exchange listing requirements.

          (b)     Stockholder Approval.  The Board may, in its sole discretion, submit any other amendment to the Plan for stockholder approval, including, but
not limited to, amendments to the Plan intended to satisfy the requirements of Section 162(m) of the Code and the regulations thereunder regarding the exclusion of performance-based compensation from the limit on corporate deductibility of compensation
paid to certain executive officers.

          (c)     Contemplated Amendments.  It is expressly contemplated that the Board may amend the Plan in any respect the Board deems necessary or advisable
to provide eligible Employees with the maximum benefits provided or to be provided under the provisions of the Code and the regulations promulgated thereunder relating to Incentive Stock Options and/or to bring the Plan and/or Incentive Stock Options
granted under it into compliance therewith.

          (d)     No Impairment of Rights.  Rights under any Stock Award granted before amendment of the Plan shall not be impaired by any amendment of the Plan
unless (i) the Company requests the consent of the Participant and (ii) the Participant consents in writing.

          (e)     Amendment of Stock Awards.  The Board at any time, and from time to time, may amend the terms of any one or more Stock Awards; provided,
however, that the rights under any Stock Award shall not be impaired by any such amendment unless (i) the Company requests the consent of the Participant and (ii) the Participant consents in writing.

13.     TERMINATION OR SUSPENSION OF THE PLAN.

          (a)     Plan Term.  The Board may suspend or terminate the Plan at any time.  Unless sooner terminated, the Plan shall terminate on the day before the
tenth (10th) anniversary of the date the Plan is adopted by the Board or approved by the stockholders of the Company, whichever is earlier.  No Stock Awards may be granted under the Plan while the Plan is suspended or after it is terminated.

          (b)     No Impairment of Rights.  Suspension or termination of the Plan shall not impair rights and obligations under any Stock Award granted while the
Plan is in effect except with the written consent of the Participant.

14.     EFFECTIVE DATE OF PLAN.

          The Plan shall become effective as determined by the Board, but no Stock Award shall be exercised (or, in the case of a stock bonus, shall be granted) unless and until the Plan
has been approved by the stockholders of the Company, which approval shall be within twelve (12) months before or after the date the Plan is adopted by the Board.

15.     CHOICE OF LAW.

          All questions concerning the construction, validity and interpretation of this Plan shall be governed by the law of the State of Delaware, without regard to such state's
conflict of laws rules.<PAGE>

                                                                   EXHIBIT 10.15

                                    SeaMED
                                    ------
                               A PLEXUS.Company
                        Professional Services Agreement
       (For Use with Manufacturing Services for Medical Customers Only)

This Agreement is hereby entered into on this 17th day of February, 2000 by and
between Rita Medical Systems, Inc., of 967 N. Shoreline Boulevard, Mountain
View, CA 94043, (hereinafter "Customer") and Plexus Corp. of 55 Jewelers Park
Drive, Neenah, WI 54956, (along with its wholly-owned subsidiaries Plexus
Technology Group, Plexus Electronic Assembly and SeaMED, a Plexus Company,
hereafter collectively referred to as "Plexus".)

A.   MANUFACTURING PHASE
------------------------

The terms and conditions set forth in this Section A, Manufacturing Phase,
Section B, Medical Device Provisions, as well as the terms and conditions set
forth in Section C, Standard Terms and Conditions, shall be applicable to this
portion of the Agreement. The parties may conduct a mutual review of component
pricing, material mark-up, and labor on a semi-annual basis. Unit prices shall
not be increased or decreased more often than semi-annually unless the quantity
on order changes, or in the event of an engineering change that impacts either
material or labor costs. [***] Attachment C provides an example of unit cost
calculations for various production rates. As part of the semi-annual reviews,
Plexus shall review unit costs at various production rates and shall provide
Customer with updated unit costs at these production rates. Customer's Purchase
Orders for quantities outside the scope of Attachment C shall be mutually
negotiated. The estimated quantity of Products is a factor used to determine
unit pricing. In the event of a significant quantity change, either increasing
or decreasing the estimated quantity of assemblies, the parties agree to
evaluate and negotiate the impact and timing of unit price adjustments.

1.   DEFINITIONS
----------------

For the purpose of this Manufacturing Phase:

"Assemblies" shall mean finished Product.

"Long Lead Time Component(s)" shall mean all of those individual parts and
materials whose current lead times extend beyond forty (40) business days. The
Long Lead Time Components may, from time to time, be reviewed by Plexus and
Customer, at the request of either party due to possible changes in market
conditions of supply and demand affecting the procurement by Plexus of the
Components and/or Long Lead Time Components for the assemblies hereunder. Any
changes resulting from such review shall be with the mutual written agreement of
Plexus and Customer.

"NCNR Component(s)" shall mean those parts that are not cancelable once placed
on order with Plexus suppliers, and are not returnable once delivered to Plexus.
The NCNR Component(s) may, from time to time, be reviewed by Plexus and
Customer, at the request of either party due to possible changes in market
conditions of supply and demand affecting the procurement by Plexus of the
Components and/or NCNR Component(s) for the assemblies hereunder. Any

*** Material has been omitted pursuant to a request for confidential treatment
and such material has been filed separately with the SEC.
<PAGE>

changes resulting from such review shall be with the mutual written agreement of
Plexus and Customer.

"Special Component(s)" shall mean those parts that have special procurement
conditions such as limited change parameters or other special liability
conditions that are required by Plexus' suppliers. The Special Component(s) may,
from time to time, be reviewed by Plexus and Customer, at the request of either
party due to possible changes in market conditions of supply and demand
affecting the procurement by Plexus of the Components and/or Special
Component(s) for the assemblies hereunder. Any changes resulting from such
review shall be with the mutual written agreement of Plexus and Customer.

"Monthly Rolling Quantity Forecast of Delivery Requirements" shall mean the
written documents provided to Plexus by Customer each month indicating the
delivery requirements projected for the next twelve (12) months.

2.   AUTHORIZATION OF WORK/PROCUREMENT OF MATERIALS
---------------------------------------------------

The following terms will apply assuming Customer's credit has been established
to Plexus' satisfaction:

a)   The purpose of this section is to define the methods under which Plexus
will procure materials to support manufacturing of product for the Customer. The
intent is to provide the Customer with flexibility to alter and/or cancel
schedules within a reasonable period of time while at the same time minimizing
Plexus liability that is a result of those alterations and cancellations. In
order to offer the best possible price, Plexus does not attempt to build
unanticipated carrying charges into its price. When changes in Customer
requirements occur that cause Plexus to incur unanticipated expenses that are
the result of Customer actions, the Customer is expected to reimburse Plexus for
the costs incurred.

For each assembly to be manufactured, Plexus establishes a manufacturing lead
time, which is the number of business days it will take, on average, to receive
and kit all components, assemble, test and ship the lot. Manufacturing lead time
shall be established during the pre-production phase of the program. Plexus
schedules all components for a particular lot of assemblies to arrive one
manufacturing lead-time prior to the Customer due date. Plexus then uses this
information, together with the Forecast and Purchase Order information as
defined below, to place commitments to its suppliers for materials.

b)   Customer shall place purchase orders for the first six (6) months of
production and maintain six (6) months of firm purchase orders on a month to
month rolling basis. Customer will provide Plexus on a monthly basis with a
minimum of twelve (12) month schedule of demand for product. The schedule will
show firm orders for months 1-6 and forecasted demand for months 7/12. Customer
authorizes Plexus to procure, as material lead times dictate, the material to
support 100% of Buyers forecasted requirements for months 7 through 9. On a
quarterly basis Plexus will place orders for material for months 7 through 9 of
the current forecast in order to lot size Printed Circuit Board Assemblies and
to determine economic order quantity buys or components or unique parts. Months
10, 11 and 12 are provided for Plexus

*** Material has been omitted pursuant to a request for confidential treatment
and such material has been filed separately with the SEC.
<PAGE>

visibility and may be utilized by Plexus to request additional material
authorizations from Customer. Prior to entering full production Customer and
Plexus will review the final bill of material, discuss material lead times and
production ordering parameters. Customer and Plexus agree to develop a material
ordering plan which will ensure timely delivery of material to meet production
objectives, while limiting the exposure to materials in the event of a program
shut down.

c)   Schedule Changes:

The Customer may request a change to the delivery schedule at any time. Schedule
changes can have an extraordinary effect on the amount of inventory at Plexus,
the impact for which is not considered in the original cost of the assembly.
Frequent schedule changes may result in additional administrative charges
including but not limited to administrative charges required for Plexus to
reschedule component deliveries.

*** Material has been omitted pursuant to a request for confidential treatment
and such material has been filed separately with the SEC.
<PAGE>

Customer and Plexus recognize that each program is unique and will require
program specific ordering parameters. These parameters are mutually agreed to
after the bill of material is finalized and production quantities are provided
to Plexus in the form of a purchase order or delivery forecast. The parameters
set forth below offer a typical scenario where the Customer may, without cost or
liability, but with the assent of Plexus, reschedule deliveries of Products
already on order. Customer may request to move in delivery dates of quantities
on order. Plexus will complete an analysis of material availability and will
provide Customer with estimated ship dates based on material availability.
Likewise, Customer may request to move out delivery dates of quantities on
order. Plexus will complete an analysis of the impact of this change to material
on hand and on order. If Customer chooses to move out deliveries and material is
already at or shipping to Plexus's facility, Customer may be charged an
inventory deposit for this material as set forth below.

                    Production Schedule Ordering Parameters
                    ---------------------------------------

--------------------------------------------------------------------------------
0 to 3 Months       Firm PO's, Schedule unchangeable
--------------------------------------------------------------------------------
4 to 6 Months       Firm P0's. May move up to 20% of scheduled deliveries on
                    PO's out 30 days without incurring an inventory deposit, or
                    in 30 days depending on material availability.
--------------------------------------------------------------------------------
7 to 9 Months       May move up to 30% of scheduled deliveries on PO's out 60
                    days without incurring an inventory deposit, or in 60 days
                    depending on material availability. Deliveries extended >60
                    days will require an inventory deposit.
--------------------------------------------------------------------------------

Customer may request to increase the total quantity of Products on order. For
quantity increases, Plexus will make its best effort to obtain the components
necessary to meet Customer requirements. Plexus will complete an analysis of
material availability and will provide Customer with estimated ship dates based
on material availability. However, Plexus may be unsuccessful in obtaining all
of the components required to meet the Customer's increased requirements. In
that situation, Plexus will complete an analysis of material availability and
will provide Customer with estimated ship dates based on material availability.
Customer may request to decrease the total quantity of Products on order. If
Customer decreases the total quantity of Products on order, all non-cancelable,
non-returnable material procured in accordance with Customer's original Purchase
Order schedule will be the responsibility of Customer.

d)   Engineering Change

The term "Engineering Change(s)" (hereinafter called "EC" or "EC's") shall mean
those mechanical, software, or electrical design and/or specification and
requirement changes which, if made to the assemblies to be delivered hereunder,
would affect the schedule performance, reliability, availability,
serviceability, appearance, dimensions, tolerance, safety or purchase price of
such assemblies or which would require additional approval test.

*** Material has been omitted pursuant to a request for confidential treatment
and such material has been filed separately with the SEC.
<PAGE>

Plexus may determine that Engineering Changes will affect its ability to
maintain the delivery schedule, due to the lead time of newly specified parts
and/or the impact of substantial rework or modification. Under these
circumstances, Plexus reserves the right to define a new schedule for delivery
and treat this as a Schedule Change, with the Customer liability as defined
under the Schedule Change condition.

Plexus shall process engineering changes per the agreed upon Document Change
Control Agreement, attached hereto and made a part hereof as Attachment A. Upon
receipt, Plexus shall review Customer's proposed EC and Plexus shall give to
Customer a written evaluation of the EC, stating Plexus' cost to implement the
EC (including the cost to modify any tooling), the excess quantity of Components
and/or Long Lead Time Components, NCNR Components and/or Special Components
Plexus has inventoried and/or has on order with its Components and/or Long Lead
Time Components, NCNR Components and/or Special Components suppliers that are
unusable for any other assembly requirement and excess due to the EC, and
associated costs and expenses such Components and/or Long Lead Time Components,
NCNR Components and/or Special Components that Customer shall be liable for and
the cost savings, if any, resulting from the EC, and the expected effect on the
schedule, availability and/or purchase price of such assemblies, or which may
require additional approval tests by Customer.

e)   Customer Supplied Parts

In the event the Customer supplies material to Plexus for use in the
manufacturing of the product, Customer agrees to supply the material on time and
in accordance with purchase orders placed by Plexus. Customer supplied material
will be subject to normal incoming inspection, and the value of the incoming
material will be included in the unit price. For purposes of payment relating to
this section only, Plexus and Customer agree to develop a method for providing
Customer with payment for such accepted customer supplied material such that
Customer will not be charged twice for any individual customer supplied
material. If material supplied by Customer is rejected or not delivered on time,
therefore preventing Plexus from completing and shipping product, Plexus may
invoice Customer for the full unit price as listed on Customer's purchase order.

f)   Minimum Component Purchases

Plexus may have to place orders for quantities of components in excess of that
required to support Customer requirements. This may be as a result of minimum
order size requirements or standard package sizes from the supplier. Plexus and
Customer will work together using best efforts to identify components that
require or may be likely to require a minimum buy prior to the initial build.
However, the Customer's responsibility for minimum component purchases is not
solely confined to this list since additional components may require minimum buy
purchases at any time. Plexus shall provide Customer with periodic updates as
well as inventory reports showing excess and obsolete components. The Customer
will agree to have the cost of the excess components amortized over a maximum of
six (6) month's requirements, or will place a purchase order separately for the
excess components.

g)   Cancellation

*** Material has been omitted pursuant to a request for confidential treatment
and such material has been filed separately with the SEC.
<PAGE>

Customer may cancel requirements defined in orders and/or forecasts at any time
before the scheduled delivery date. Any assembly requirements canceled within
the manufacturing lead-time of the scheduled delivery date will be invoiced at
the full agreed to price for the completed assembly.

For assembly requirements canceled outside the manufacturing lead time of the
scheduled delivery date, Customer's liability to Plexus will be the value of the
components in Plexus' inventory (including the full markup as defined in the
Plexus quotation), and other components for which Plexus has liability but which
are not in Plexus inventory, as well as payment for any and all work-in-process
(WIP) manufacturing costs and expenses, and reasonable administrative costs and
expenses. Plexus will deliver an itemized list of these costs to customer.
Customer agrees to pay the costs identified by Plexus within ten (10) business
days of notification of such costs.

To help minimize the impact of cancellation charges, Plexus will attempt to
restock components at the supplier, resell the components, and/or utilize the
components on non-customer assemblies.

3.   PAYMENT
------------

As full compensation for the assemblies and spare parts (i.e. to include but not
limited to components shipped to Customer for field service) provided by Plexus
hereunder and its obligations contained herein. Customer will make payments
subject to terms of net amount due thirty (30) days following the date of the
invoice. Unless stated otherwise, prices quoted are F.O.B. Plexus' manufacturing
facility. Unless specifically stated otherwise, all quoted prices are firm for
thirty (30) days from the date of quotation. Quotations are based on drawings,
specifications, and other written information available to Plexus at the time of
quotation. Any additional data supplied at the time of purchase may necessitate
price adjustments. Any manufacturer's tax, retailer's occupation tax, use tax,
sales tax, excise tax, or tax of any nature whatsoever imposed on or measured by
the transaction between Plexus and Customer shall be paid by the Customer in
addition to the prices quoted or invoiced. In the event Plexus is required to
pay such tax, the Customer shall reimburse Plexus therefore, within ten (10)
days of written demand by Plexus to the Customer for such reimbursement. If the
transaction between Plexus and the Customer is exempt from all such taxes,
Customer shall provide Plexus with a tax exemption certification or other
document acceptable to all taxing authorities at the time the order or contract
is submitted.

4.   WARRANTY
-------------

PLEXUS EXPRESSLY WARRANTS THE WORK AS SET FORTH HEREIN. PLEXUS MAKES NO OTHER
WARRANTIES, EITHER EXPRESS OR IMPLIED (INCLUDING WITHOUT LIMITATION WARRANTIES
AS TO MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSES). IN ADDITION, THE
FOLLOWING SHALL CONSTITUTE THE EXCLUSIVE REMEDIES FOR CUSTOMER FOR ANY BREACH BY
PLEXUS OF ITS WARRANTIES HEREUNDER.

*** Material has been omitted pursuant to a request for confidential treatment
and such material has been filed separately with the SEC.
<PAGE>

Plexus warrants the assemblies against all defects in workmanship where the
assemblies do not conform to the agreed upon manufacturing specifications, for a
period of twelve (12) months from date of delivery to Customer's end-user, not
to exceed 16 months from date of invoice from Plexus, provided agreed upon
testing is conducted by Plexus prior to shipment, except as set forth below.
Plexus shall repair or replace, at Plexus' option and free of charge, any
portion of the assemblies which is returned to Plexus' factory securely
packaged, insured and with freight pre-paid within the warranty period, and
which upon examination Plexus determines in its sole discretion to be defective
in workmanship. Plexus will return the repaired or replaced assemblies to
customer with freight pre-paid. Plexus will pay for inbound freight for any new
units delivered dead on arrival (DOA) to Customer. DOA is defined as any product
that does not perform in compliance with the applicable mutually agreed upon
specifications upon receipt by Customer. Plexus agrees to pay return freight to
Customer and method of shipment will be consistent with the method of inbound
freight to Plexus.

This Warranty does not apply to:

a)   Design deficiencies.  Plexus expressly disclaims any warranty
responsibility for design deficiency, and for infringement for the like.

b)   Any modifications and/or alterations made to the Assemblies, or any portion
thereof, without the express written authorization of Plexus obtained in
advance. If this is the case, all warranties made herein are invalid and
Customer shall have no further remedies hereunder against Plexus.

c)   Any defect, loss or damage resulting from theft, loss, fire, misuse, abuse,
negligence, vandalism, acts of God, accident, casualty, power failures or
surges, alteration, modification or failure to follow installation, operation or
maintenance instructions, or any other cause beyond Plexus' reasonable control.

d)   Any defect, unless written notice of the defect is given by the Customer to
Plexus as soon as practical after the defect first appears. The right to make a
claim under this warranty expires twelve (12) months from the date of delivery
to Customer's end-user, not to exceed 16 months from date of invoice from
Plexus.

e)   Components incorporated into the assemblies.

In the event of any recall of any Product, caused by Plexus's sole negligence,
and within product warranty as defined, (i) Plexus shall repair or replace, at
Plexus' sole discretion, the recalled Product without charge to Customer, and
(ii) Plexus shall reimburse Customer for its reasonable out-of-pocket expenses
incurred in connection with such recall up to a maximum of $100,000.

IN NO EVENT, REGARDLESS OF CAUSE, SHALL EITHER PARTY BE LIABLE FOR INCIDENTAL,
INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES OR LOSSES OF ANY KIND, WHETHER IN
CONTRACT OR IN TORT, ARISING FROM ITS PERFORMANCE UNDER THIS SECTION.

5.   TEST EQUIPMENT
-------------------

*** Material has been omitted pursuant to a request for confidential treatment
and such material has been filed separately with the SEC.
<PAGE>

Unless otherwise noted, any test equipment quoted herein and built by Plexus is
warranted to be free from defects in material and workmanship for a period of
ninety (90) days from the date of certification. After the warranty period the
equipment will be repaired on a time and materials basis. Labor will be charged
at the current billing rate. Parts will be charged at cost plus 25%. Travel
expenses will be added to any repairs including travel between Plexus and/or one
of its affiliates. All dedicated test/burn in fixtures will be progress billed
monthly up to 95% of the program cost. The remaining 5% is due upon fixture
certification.

6.   DOCUMENTATION
------------------

Unless Plexus is or has generated the documentation for the Customer as part of
its services to the Customer, then the Customer is responsible for supplying
Plexus with complete documentation. This includes, at a minimum, (three) 3
complete and current sets of documentation including, at a minimum, all prints,
softwares, artwork, and bill of materials with manufacturer and part number, and
any specifications, including test specializations or procedure, called for on
any customer prints. It is the Customer's responsibility to assure that Plexus
receives timely notification of any changes to the documentation, and updated
prints reflecting the changes.

7.   TOOLING
------------

All tooling produced or obtained for the assemblies delivered hereunder and paid
for by Customer shall become and remain the property of Customer at the time
payment in full is received for the tooling by Plexus. Such tooling shall be
used by Plexus only for the benefit of Customer, and shall be delivered to
Customer upon request. If Customer requests the return of any tooling from
Plexus and Plexus determines the return of such tooling prevents Plexus from
providing the assemblies to Customer, then Plexus shall inform Customer in
writing, and Customer and Plexus shall negotiate a mutually acceptable
resolution.

Customer, at its sole discretion, may consign to Plexus, items, including, but
not limited to, materials and/or equipment relating to the production and/or
testing of the assemblies at Plexus' location. The material and/or equipment
shall be utilized by Plexus only for the production and/or testing of the
assemblies. Customer shall assist Plexus in installing the materials and/or
equipment and shall provide training and maintenance instructions, if requested
by Plexus or required by Customer. Customer shall be responsible for repairing,
upgrading, replacing and/or maintaining the materials and/or equipment consigned
to Plexus. However, Plexus shall provide routine maintenance.

8.   TERMINATION AND CANCELLATION OF MANUFACTURING PHASE
--------------------------------------------------------

During the Manufacturing Phase, either party shall have the right to terminate
any or all activities under this agreement for any reason and at any time upon
six (6) months prior written notice to the other party. Plexus agrees to
immediately terminate the specified activity pursuant to this Agreement upon
termination or cancellation. If this entire Agreement is terminated, Plexus
shall complete all existing Customer POs as specified below unless otherwise
specified by Customer. Customer agrees to reimburse Plexus for reasonable and
allowable expenses directly incurred by

*** Material has been omitted pursuant to a request for confidential treatment
and such material has been filed separately with the SEC.
<PAGE>

Plexus including, but not limited to, packaging and related transportation costs
and expenses, and the return to Customer of any Customer owned material(s),
tools, equipment and/or any other related items, consistent with Section A2
Cancellation, above. Customer and Plexus shall negotiate a settlement of any
other reasonable and allowable expenses directly incurred by Plexus.

If this entire agreement is terminated, then Plexus shall:

a)   Deliver to Customer all completed assemblies which conform to the
applicable and then current specifications and requirements; and

b)   Return to Customer, at Customer's expense, all tooling, equipment,
Components and/or Long Lead Time Components, drawings, specifications,
documentations and supplies that are owned by Customer pursuant to the Agreement
(in the event of Plexus' material breach and the failure of Plexus to cure such
breach 60 days after receiving written notice thereof from Customer then Plexus
shall pay for freight costs associated with returning all tooling, equipment,
Components and/or Long Lead Time Components, drawings, specifications,
documentations and supplies that are owned by Customer pursuant to the
Agreement); and

c)   Prepare and submit to Customer an itemized document to include the quantity
of assemblies in the production process.

Plexus shall complete and customer agrees to pay for any work in process and
open purchase orders if so requested by Customer as if no termination notice was
given. Customer further agrees to pay for all material ordered in accordance
with Section A2 above or as otherwise authorized in writing by Customer.

B.   MEDICAL DEVICE PROVISIONS
------------------------------

The terms and conditions set forth in this Section B, Medical Device Provisions,
Section A, Manufacturing Phase, as well as the terms and conditions set forth in
Section C, Standard Terms and Conditions, shall be applicable to this portion of
the Agreement.

Engineering Phase:
------------------

1.   Plexus shall be in substantial compliance with design controls as defined
by its product development medical device quality procedures for the device
designs covered by this contract. Plexus responsibilities under these provisions
include:

a)   contributions to the Device History File (DHF) shall be limited to those
items identified in the deliverables section of the project Proposal and/or
Project Plan;

b)   Contributions to the Design Master Record (DMR) shall be limited to those
items identified in the deliverables section of the project Proposal and/or
Project Plan;

*** Material has been omitted pursuant to a request for confidential treatment
and such material has been filed separately with the SEC.
<PAGE>

c)   Maintenance of quality system quality records, as defined by Plexus
Technology Group's Document Retention Chart, (e.g., Internal Audit Results, QIP
database, Supplier Records, Management Review Meeting Records, etc.) which are
not provided to the customer.

2.   Customer is responsible for identifying all applicable laws and
regulations, including the Food, Drug and Cosmetic Act, and compliance with
those regulations for all devices covered by this contract.

Manufacturing Phase:
--------------------

1.   Customer is responsible for ensuring that the devices covered by this
contract comply with all applicable laws and regulations, including the Food,
Drug and Cosmetic Act and implementing regulations. Customer responsibilities
under these provisions, include but are not limited to the following:

a)   Establishing the finished device specifications.

b)   Ensuring that governmentally-required marketing authorizations, including
any necessary Food and Drug Administration (FDA) approvals or clearances, have
been obtained.

c)   Determining the content of any label or labeling.

d)   Making any required reports to governmental entities, including but not
limited to Medical Device Reports.

e)   Determining whether any recall or other corrective action is required or
appropriate, and developing, implementing and financing any voluntary or
mandatory recall or corrective action.

f)   Reviewing and approving the quality system prior to production of the
devices.

2.   Plexus will provide Customer ongoing access to its facilities and
procedures for quality assurance related to the devices covered by this
contract. Plexus authorizes Customer to conduct periodic quality systems audits
of the manufacturing processes and quality systems related to this contract.
Plexus will manufacture the devices covered by this contract in accordance with
its procedures for manufacturing components of medical devices or finished
medical devices, as applicable.

3.   Customer will provide Plexus with sufficient information to verify,
calibrate, operate, test and maintain any Customer supplied equipment.

4.   Customer shall be responsible for the software validation of any embedded
product software and the validation of all Customer supplied: (1) test equipment
or test software; (2) production equipment or software; and (3) firmware. Plexus
is responsible for the validation of any Plexus software used in production in,
or as part of the Quality System. The responsibilities described in this section
also apply to any revisions of any software.

*** Material has been omitted pursuant to a request for confidential treatment
and such material has been filed separately with the SEC.
<PAGE>

5.   The Customer will provide Plexus with copies of the specifications and
written certification that the validation reports for the items listed in
Section #4 above have been performed prior to the production of the devices.

6.   Customer is responsible for defining and validating the finished device
packaging. The Customer will provide Plexus with written certification that the
packaging validation has been performed prior to the production of the devices.

7.   Plexus is responsible for conducting and documenting corrective and
preventive actions based upon the analysis of the quality data available to
Plexus. Quality data or information known to the Customer, but not provided to
Plexus, shall not be included in the analysis of quality data, and the Customer
shall be responsible for the analysis of data not provided to Plexus.

8.   Any Customer initiated request for change to a specification, method,
process or procedure or customer supplied equipment will be evaluated by Plexus,
and Plexus reserves the right to decline to make such change. Customer is
responsible for verification and/or validation of such changes. Customer shall
reimburse Plexus for any costs Plexus incurs in making and/or implementing such
changes.

9.   Plexus shall notify Customer of significant changes in specifications,
methods, processes or procedures that could affect the quality of the devices
covered by this contract, and, as to any such change, Customer and Plexus shall
decide jointly whether, how and when to implement such change, and who shall be
responsible for verification and/or validation of such changes. Customer and
Plexus shall also decide jointly who will be responsible for the costs
associated with such changes.

10.  The Customer must define any traceability requirements. Plexus is
responsible for implementing the defined manufacturing level traceability
requirements and for ensuring that the appropriate manufacturing level
traceability records and associated records are retained for the duration of the
contract.

11.  Unless otherwise specified in the contract, Plexus is not responsible for
ensuring traceability of the devices covered by this contract after distribution
to the end user(s).

12.  Plexus is responsible for retaining the appropriate manufacturing records
as required. When the contract between Plexus and the Customer terminates,
Plexus shall forward all applicable documentation and records to the Customer,
upon request.

13.  Customer may authorize in writing the release of nonconforming components
or devices covered by this contract. The Customer must assess whether the use of
the nonconforming product will affect any regulatory submittals or requirements,
and accept responsibility therefore.

14.  Customer will promptly provide to Plexus copies of all complaints received
by Customer that refer or relate to an assembly manufactured by Plexus and all
adverse event reports to a governmental entity that refer or relate to an
assembly manufactured by Plexus. Plexus will

*** Material has been omitted pursuant to a request for confidential treatment
and such material has been filed separately with the SEC.
<PAGE>

provide to Customer information regarding any complaints Plexus receives about
the product in which the devices covered by this contract are incorporated.

15.  Sections C.(5) and C.(7) "Liability and Indemnification" & "Compliance with
Regulations and Standards", respectively, both a part of Section C "Standard
Terms and Conditions" of this Agreement is further supplemented to provide that
the indemnification of Plexus will further cover Customers' failure to comply
with applicable laws and regulations, including but not limited to the Food,
Drug and Cosmetic Act and implementing regulations.

C.   STANDARD TERMS AND CONDITIONS
----------------------------------

The terms and conditions set forth in this Section C, STANDARD TERMS AND
CONDITIONS shall be applicable to Section A, Manufacturing Phase, as well as the
terms and conditions set forth in Section B, Medical Device Provisions of this
Agreement.

1.   MUTUAL COOPERATION
-----------------------

Plexus represents that it will pursue the Agreement to the best of its ability
and in the best interest of the Customer, and the Customer represents that it
will cooperate with Plexus in reaching the objectives of the Agreement. Plexus
will appoint a project manager for the duration of the Agreement and will
require the Customer to establish one person to coordinate all activities
through. In the event that the project manager is not operating in the best
interest of the Customer, the Customer shall contact Plexus to discuss Agreement
related concerns and/or complaints.

2.   CONFIDENTIAL INFORMATION
-----------------------------

Plexus and the Customer will use best efforts to prevent the disclosure of any
confidential information, unless specifically instructed otherwise in writing by
the disclosing party, and excepting in such instances where Plexus may be
compelled by law to make disclosures. The mechanisms for controlling and
processing confidential information may be covered under a separate Confidential
Disclosure Agreement (if required).

3.   FORCE MAJEURE
------------------

Plexus shall not be liable for any delay in or failure of performance under this
agreement due to any contingency beyond Plexus' control, including, but not
limited to, an act of God, war, insurrection, fire, riot, strike or labor
dispute, sabotage, act of public enemy, flood, storm, accident, equipment
failure, inability to obtain suitable or sufficient labor or material, laws or
regulations, or any other cause beyond its reasonable control.

4.   INTELLECTUAL PROPERTY RIGHTS
---------------------------------

All patents, copyrights, trademarks, or other rights pertaining to inventions,
developments, or improvements made in the course of the work, and funded by the
Customer, are the property of Customer. Plexus will, upon written direction from
Customer, execute any and all papers and documents prepared or submitted by
Customer as may be reasonably required to transfer or

*** Material has been omitted pursuant to a request for confidential treatment
and such material has been filed separately with the SEC.
<PAGE>

secure to Customer full title and authority over such rights. Plexus will be
compensated by Customer for time and expense as incurred in this obligation at
the then current billing rates for those of its employees necessary for these
purposes.

Customer agrees that it shall assume all responsibility for determining whether
the assemblies to be designed and assembled infringe on any patent, copyright or
trademark, and Customer shall indemnify and hold harmless Plexus from any
liability, including legal costs and expenses, damages and attorney fees arising
from any claim demand or suit, including a claim by Customer, based on
allegations or claims that the assemblies or any design, patent, copyright, or
trademark sought to be obtained or obtained by Customer as a result of this
agreement constitutes an infringement of any patent, trademark or copyright of
the United States or any foreign county.

In the event any such claim or suit is asserted or instituted against Plexus,
Plexus shall promptly notify Customer of the assertion of any such allegation or
claim. Customer shall thereupon assume responsibility for and conduct the
defense of each assertion or suit at its expense, and reasonable information and
assistance for the defense of same shall be provided by Plexus for which Plexus
will be compensated for time and expenses at its then current billing rate.
Plexus shall have the right, at its expense, to be represented in the defense of
any such assertion or suit by counsel of its own selection.

The prices quoted do not include, unless specifically stated otherwise, the cost
for testing and/or submittals for assembly approvals or any annual file
maintenance fee, such as for UL, VDE, CSA or FCC. Plexus will assist Customer in
obtaining such approvals and charge for same services at Plexus' current hourly
billing rate.

5.   LIABILITY AND INDEMNIFICATION
----------------------------------

Plexus will use its discretion to pursue the Agreement in the best interest of
Customer. Plexus will be under no liability to Customer or otherwise for its
choice of methods employed, the character or tests and experiments performed,
the results obtained, nor for the use which shall thereafter be made by Customer
of such results. IT IS UNDERSTOOD THAT OTHER THAN THE WARRANTY SET FORTH IN
SECTION A4, NO OTHER GUARANTEES OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED,
ARE GIVEN BY PLEXUS, INCLUDING, BUT NOT LIMITED TO ANY WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. PLEXUS SHALL NOT BE LIABLE
FOR ANY INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS)
SUSTAINED OR INCURRED IN CONNECTION WITH THIS AGREEMENT.

Customer will fully indemnify and hold harmless Plexus from any and all
liability, claims demands, costs and expense arising out of the use,
publication, and/or marketing of the results of the assemblies or test results
provided by Plexus, the functioning of the assemblies or the product(s) which
they are a part of, or any other matter resulting from Plexus' performance under
this Agreement, whether such liability, claims or demands be in the nature of
patent, trademark or copyright infringement, public or product liability,
contract liability, or otherwise during or following the terms of this
Agreement, and Customer shall, at its own expense, defend any and

*** Material has been omitted pursuant to a request for confidential treatment
and such material has been filed separately with the SEC.
<PAGE>

all such actions based thereon and shall pay all attorney's fees and cost and
other expenses arising therefrom.

Plexus will not be liable for errors, or expenses which may be incurred in its
performance of this work which results from the engineering and/or design of the
Assemblies, or from Plexus' reliance upon information, technological records,
sketches, drawings, or prototypes furnished by Customer or Customer's design
engineering firm. Customer will forthwith, during the term of this Agreement,
notify Plexus of any and all information, technology changes, or other facts
relevant to any aspect or phase of the Agreement.

6.   ARBITRATION
----------------

All rights and remedies conferred by this Agreement, by any other instrument, or
by law are cumulative and may be exercised singularly or concurrently. If any
provision of this Agreement is held by any court or governmental agency to be
invalid, such invalidity shall not affect the enforceability of any other
provision(s) hereof. This Agreement and any Purchase Orders issued hereunder
shall be governed by and interpreted in accordance with the laws of the State of
Wisconsin. Unless otherwise agreed to in writing by the parties, any controversy
or claim arising out or relating to this Agreement, or the parties' decision to
enter into this Agreement, or the breach thereof, shall be settled by
arbitration through the American Arbitration Association and in accordance with
the Commercial Arbitration Rules of the American Arbitration Association. The
arbitration proceeding shall be conducted and presided over by a single neutral
arbitrator chosen pursuant to American Arbitration Association procedures.
Decision of the arbitrator shall be final, binding, and not subject to appeal or
review; provided that, either party may request that the arbitrator review and
reconsider his or her decision, in whole or in part. Judgment upon the award
rendered by the arbitrator may be entered in any court having jurisdiction
thereof. The arbitration shall be held in Neenah, Wisconsin and the arbitrator
shall apply the substantive law of Wisconsin except that the interpretation and
enforcement of this arbitration provision shall be governed by the federal
Arbitration Act. The arbitrator shall not award either party punitive damages
and the parties shall be deemed to have waived any right to such damages.

7.   CONSENT TO JURISDICTION AND APPLICABLE LAW
-----------------------------------------------

The parties hereby irrevocably submit to the jurisdiction of the courts of the
State of Wisconsin in any action or proceeding arising out of or relating to
this Agreement, and the parties hereby irrevocably agree that all claims in
respect of such action or proceeding may be determined by such courts. The
parties hereby waive, to the fullest extent possible, the defense of an
inconvenient forum to the maintenance of such action or proceeding, and the
parties agree that a final judgement in any action or proceeding shall be
conclusive and may be enforced in other jurisdictions by suit on the judgement
or in any other matter provided by law.

The parties hereby agree that this Agreement shall be governed by and will be
construed in accordance with the laws of the State of Wisconsin, irrespective of
the conflicts of laws provisions thereof.

*** Material has been omitted pursuant to a request for confidential treatment
and such material has been filed separately with the SEC.
<PAGE>

8.   NO RECRUITING
------------------

Plexus and the Customer agree that during the term of this program and for
twelve (12) months thereafter, it shall not solicit or recruit (even though
professional recruiters) the employees of the other. This shall not preclude an
employee of either Plexus or the Customer from independently pursuing and
securing employment opportunities with the other on such employee's own
initiative.

9.   ENTIRE AGREEMENT
---------------------

This Agreement, along with the Proposal and/or Project Plan, and Confidential
Disclosure Agreement and/or quotation (if any) and Plexus' invoices, contains
the entire understanding of the parities pertaining to the subject matter
hereof, and no other agreements, oral or otherwise, shall be deemed to exist or
to bind the parties. Notwithstanding anything to the contrary contained herein,
the parties hereto agree that the terms and conditions set forth herein and in
Plexus' invoices, Proposal and/or Project Plan and Confidential Disclosure
Agreement (if any), shall supersede any and all terms and conditions submitted
by the Customer in any document, including but not limited to any terms and
conditions contained in the Customer's purchase order. This agreement may not be
modified or terminated orally, and no claimed modification, termination, or
waiver shall be binding unless in writing and signed by both parties.

Accepted and agreed to:

<TABLE>
<CAPTION>
RITA MEDICAL SYSTEMS, INC.                             PLEXUS CORP.
<S>                                                    <C>
                                                       ENGINEERING AUTHORIZATION:

By: /s/ Barry Cheskin                                  By: /s/
    ----------------------------------------               -------------------------------------

Title: President and Chief Financial Officer           Title: Vice President of Engineering
       -------------------------------------                  ----------------------------------

Date: February 24, 2000                                Date: February 17, 2000
      --------------------------------------                 -----------------------------------

                                                       MANUFACTURING AUTHORIZATION:

                                                       By: /s/ Don Reid
                                                           -------------------------------------

                                                       Title: Vice President and General Manager
                                                              ----------------------------------

                                                       Date: February 17, 2000
                                                             -----------------------------------
</TABLE>

*** Material has been omitted pursuant to a request for confidential treatment
and such material has been filed separately with the SEC.
<PAGE>

                Attachments to Professional Services Agreement

Attachment A    Document Change Control Agreement

Attachment B    Project Plan (subject to revision upon mutual agreement)

Attachment C    Unit Cost Calculation to be used for Planning Purposes

Attachment D    Specification (subject to revision upon mutual agreement)

*** Material has been omitted pursuant to a request for confidential treatment
and such material has been filed separately with the SEC.
<PAGE>

<TABLE>
<S>                                         <C>                                      <C>            <C>
[LOGO HERE]                                 Plexus Corporation                       Quote #          0
The Product Realization Company             2121 Harrison Street
                                            Neenah, WI 54957-0529                    Date:          2/28/00
                                            (920) 722-2826  Fax (920) 720-6700
================================================================================================================
Company:      Rita Medical Systems                                Project Name:      Ablation System
              967 N. Shoreline Blvd.                              Assembly #:        Model 1500
              Mountain View, CA                                   Assembly Rev:      N/A
                                                                  Assembly Name:
Attention:    Ron Steckel                                         Prepared by:       John Grein
cc:                                                               Phone:             425-398-2825
</TABLE>

<TABLE>
UNIT COST INFORMATION
<S>                                                    <S>             <C>             <C>             <C>
                                                   -------------------------------------------------------------
Estimated Annual Quantity                              [***]           [***]           [***]           [***]
                                                   -------------------------------------------------------------
Estimated Release Quantity                             [***]           [***]           [***]           [***]
                                                   -------------------------------------------------------------

I.        MATERIALS                                    [***]           [***]           [***]           [***]
II.       PCBA LABOR                                   [***]           [***]           [***]           [***]
III.      FINAL ASSY. LABOR                            [***]           [***]           [***]           [***]
IV.       ICT TEST                                      N/A             N/A             N/A             N/A
V.        FUNCTIONAL TEST                               Inc.            Inc.            Inc.            Inc.
VI.       RUN IN TEST                                   Inc.            Inc.            Inc.            Inc.
VII.      PACKAGING                                     Inc.            Inc.            Inc.            Inc.
                                                   -------------------------------------------------------------
VIII.     TOTAL                                        [***]           [***]           [***]           [***]
                                                   -------------------------------------------------------------
INVENTORY CARRY/MONTH                                  [***]           [***]           [***]           [***]
</TABLE>
See Note 3

     Notes
     -----
1.   ICT Test is not included.  PCBA design does not support ICT.
2.   Functional PCBA, System Test, Ambient Run-in Test, Electrical Safety, and
     Final Testing Inc. in Final Assy Labor.
3.   Inventory Carrying Cost/Month is based on purchasing [***] in material for
     Initial PO of [***] units. On initial PO of less than [***] units a
     carrying charge of [***] will apply from date of last shipment on Initial
     PO to date of first shipment on next PO.

NON-RECURRING CHARGES

A.   PCB TOOLING                                   [***]
B.   PCB ETF                                       [***]
C.   ICT FIXTURE                                    N/A
D.   FUNCTIONAL FIXTURE                            [***]
E.   PCBA PROCESS DEVELOPMENT                       N/C
F.   XRAY TOOLING                                   N/A
G.   SMT PROGRAMMING                                Inc.
H.   SMT STENCIL (S)                                Inc.
I.   AUTO-INSERT PROGRAMMING                        N/A
J.   CONFORMAL COATING PROG.                        N/A
K.   MANUFACTURING SETUP                           [***]
L.   OTHER                                         [***]

SPECIFIC ASSEMBLY NOTES AND ASSUMPTIONS

A.   See Previous Proposal Dated January 12, 2000.
B.   Final Assembly Labor is Estimated Within +/- 15%.

*** Material has been omitted pursuant to a request for confidential treatment
and such material has been filed separately with the SEC.
<PAGE>

C.   Current PCB Supplier is Capable of Meeting Plexus Production Requirements.
D.   PCBA process development costs up to [***] will be paid by Plexus. Rita
     Medical responsible for additional costs due
E.   to design costs.
F.
G.
H.

*** Material has been omitted pursuant to a request for confidential treatment
and such material has been filed separately with the SEC.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00011-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00011-of-00352.parquet"}]]